
|Articles|November 16, 2009
Oncology NEWS International
- Oncology NEWS International Vol 18 No 11
- Volume 18
- Issue 11
Astellas, Medivation team on prostate Rx
Astellas has partnered with Medivation to co-develop and market the oral anti-androgen, MDV3100. In September, Medivation enrolled patients in the phase III AFFIRM trial, which is evaluating MDV3100 in 1,200 men with castration-resistant prostate cancer who were previously treated with docetaxel (Doxil) chemotherapy.
Advertisement
Astellas has partnered with Medivation to co-develop and market the oral anti-androgen, MDV3100. In September, Medivation enrolled patients in the phase III AFFIRM trial, which is evaluating MDV3100 in 1,200 men with castration-resistant prostate cancer who were previously treated with docetaxel (Doxil) chemotherapy.
Articles in this issue
over 16 years ago
Measure for measure: How to make practice benchmarks meaningfulalmost 17 years ago
Ultrasound targets lymph node recurrence in breast canceralmost 17 years ago
JAMA article reignites debate over screeningalmost 17 years ago
Moving at the speed of scienceAdvertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Lenvatinib/Pembrolizumab Shows Promise After IO Progression in GYN Cancers
2
Lymphoma's Revolution: Evens & Rhodes on CLL, CAR-T, and NJ Care
3
Belzutifan Combo Improves Disease Control Vs Cabozantinib in Advanced RCC
4
FDA Issues Another CRL for Amorphous Dasatinib Receives in CML and ALL
5



















































